Sjogrens Syndrome Market: Opportunity Analysis and Forecast to 2024

"The Latest Research Report OpportunityAnalyzer: Sjogrens Syndrome - Opportunity Analysis and Forecast to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

About Sjogrens Syndrome Market

Sjgrens syndrome (SS) is a slow progressing chronic autoimmune disease, which predominantly affects middle-aged women, and is characterized by lymphocytic infiltration of the exocrine glands, mainly the lacrimal and salivary glands, resulting in reduced secretory functions and ocular and oral dryness. The syndrome can also cause many systemic manifestations, targeting various organs of the body. Current treatment of patients with SS is challenging, with few effective therapeutic agents available. Due to the multi-factorial nature of SS, agents are required to treat glandular symptoms of the disease mainly salivary and lachrymal and also any extraglandular manifestations that may arise. However, many of the agents that are available either only treat the symptoms of the disease, are used off-label for the treatment of SS, or are considered ineffective in many patients.

The SS market is now set to enter a new phase with the potential approval of the first biologic agent for SS treatment.

Highlights

Key Questions Answered

The SS market is marked by the presence of a number of unmet needs. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the SS market?
The late-stage SS pipeline includes the biologic treatment Orencia (abatacept). Will this late-stage drug make a significant impact on the SS market? Will this drug reach peak sales by the end of the forecast period?
The current SS market is dominated by the use of off-label therapies. How will the approval of the first biologic agent for the treatment of SS change the drug treatment landscape? What are the key drivers and barriers to market growth?

Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/676702

Table of Contents

1 Table of Contents 9
1.1 List of Tables 13
1.2 List of Figures 16

2 Introduction 17
2.1 Catalyst 17
2.2 Related Reports 18

3 Disease Overview 19
3.1 Etiology and Pathophysiology 19
3.1.1 Etiology 19
3.1.2 Pathophysiology 20
3.2 Symptoms 21
3.3 Diagnosis 23
3.4 Prognosis 29

4 Epidemiology 31
4.1 Disease Background 31
4.2 Risk Factors and Comorbidities 32
4.3 Global Trends 34
4.3.1 7MM Diagnosed Prevalent Cases 36
4.3.2 5EU Diagnosed Prevalent Cases 37
4.3.3 Japan Diagnosed Prevalent Cases 37
4.4 Forecast Methodology 37
4.4.1 Sources Used 41
4.4.2 Sources Not Used 43
4.4.3 Forecast Assumptions and Methods 44
4.5 Epidemiological Forecast for SS (2014-2024) 48
4.5.1 Diagnosed Prevalent Cases of SS 48
4.5.2 Age-Specific Diagnosed Prevalent Cases of Primary SS 54
4.5.3 Sex-Specific Diagnosed Prevalent Cases of Primary SS 56
4.5.4 Age-Standardized Diagnosed Prevalence of Primary SS 58
4.5.5 Ocular and Oral Manifestations 60
4.6 Discussion 61
4.6.1 Epidemiological Forecast Insight 61
4.6.2 Limitations of the Analysis 63
4.6.3 Strengths of the Analysis 63

5 Current Treatment Options 65
5.1 Overview 65
5.1.1 General Preventative Measures 68
5.2 Product Profiles - Major Brands, Cholinergic Agonists 69
5.2.1 Salagen (Pilocarpine Hydrochloride) 69
5.2.2 Evoxac (Cevimeline Hydrochloride) 77
5.3 Off-Label Treatments and Drug Classes 83
5.3.1 Tear and Saliva Substitutes 83
5.3.2 Cyclosporine Ophthalmic Emulsion - Restasis, Ikervis, Papilock Mini 86
5.3.3 Topical Ophthalmic Corticosteroids - Prednisolone, Fluorometholone, Loteprednol 93
5.3.4 Antimalarial Agents Hydroxychloroquine 97
5.3.5 Other Systemic Immunosuppressive Therapies - Methotrexate, Azathioprine, Cyclophosphamide 102
5.3.6 Systemic Corticosteroids - Prednisolone, Methylprednisolone 111
5.3.7 Biologic Agents - Rituxan (Rituximab) 117

View Report @ https://www.marketresearchreports.biz/reports/676702/opportunityanalyzer-sjogrens-syndrome-opportunity-analysis-and-forecast-to-2024-market-research-reports

6 Unmet Needs Assessment and Opportunity Analysis 127
6.1 Overview 127
6.2 Sjgrens Syndrome Treatments with Improved Efficacy 128
6.2.1 Unmet Need 128
6.2.2 Gap Analysis 130
6.2.3 Opportunity 131
6.3 Earlier Sjgrens Syndrome Diagnosis 133
6.3.1 Unmet Need 133
6.3.2 Gap Analysis 134
6.3.3 Opportunity 136
6.4 Treatment Guidelines to Improve Patient Access to Therapies 137
6.4.1 Unmet Need 137
6.4.2 Gap Analysis 139
6.4.3 Opportunity 140
6.5 Improved Public and Patient Awareness of Sjgrens Syndrome 140
6.5.1 Unmet Need 140
6.5.2 Gap Analysis 141
6.5.3 Opportunity 141

7 Research and Development Strategies 143
7.1 Overview 143
7.1.1 Evaluation of Biologic Therapies Marketed for Other Autoimmune Diseases 143
7.1.2 Inhibition of Immunological Mechanisms Involved in Sjgrens Syndrome 146
7.2 Clinical Trial Design 147
7.2.1 Patient Number 147
7.2.2 Inclusion Criteria 148
7.2.3 Efficacy Endpoints 151

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/676702

8 Pipeline Assessment 154
8.1 Overview 154
8.2 Promising Drugs in Clinical Development 154
8.2.1 Orencia (Abatacept) 154
8.3 Innovative Early-Stage Approaches 164

9 Pipeline Valuation Analysis 166
9.1 Clinical Benchmark of Key Pipeline Drugs 166
9.2 Commercial Benchmark of Key Pipeline Drugs 167
9.3 Competitive Assessment 167
9.4 Top-Line Ten-Year Forecast 170
9.4.1 US 173
9.4.2 5EU 174
9.4.3 Japan 175

10 Appendix 177
10.1 Bibliography 177
10.2 Abbreviations 191
10.3 Methodology 195
10.4 Forecast Methodology 195
10.4.1 Percent Diagnosed Patients 195
10.4.2 Percent Drug-Treated Patients 196
10.4.3 Drugs Included in Each Therapeutic Class 196
10.4.4 Launch and Patent Expiry Dates 196
10.4.5 General Pricing Assumptions 197
10.4.6 Individual Drug Assumptions 198
10.5 Physicians and Specialists Included in This Study 203
10.6 About the Authors 205
10.6.1 Analyst 205
10.6.2 Therapy Area Director 205
10.6.3 Epidemiologist 206
10.6.4 Global Director of Therapy Analysis and Epidemiology 206
10.6.5 Global Head of Healthcare 207
10.7 About GlobalData 208
10.8 Disclaimer 208

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.